Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Sponsor: Complement Therapeutics
Summary
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
Official title: A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Key Details
Gender
All
Age Range
55 Years - Any
Study Type
INTERVENTIONAL
Enrollment
75
Start Date
2025-12-30
Completion Date
2032-06-30
Last Updated
2026-03-17
Healthy Volunteers
No
Interventions
CTx001
Subretinal administration of CTx001
Locations (3)
Midwest Eye Institute
Carmel, Indiana, United States
Sierra Eye Associates
Reno, Nevada, United States
Retina Foundation of the Southwest
Dallas, Texas, United States